ArticleBMC immunology2025
Identification of sepsis pyroptosis-related genes based on single-cell sequencing technology and experimental verification.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study aimed to screen for new biomarkers for sepsis. Firstly, peripheral blood samples from 23 sepsis patients and 10 healthy volunteers were collected according to the sepsis 3.0 criteria and analyzed by RNA-seq. A total of 876 pyroptosis-related genes were sourced from the Genecards database. Weighted gene co-expression network analysis (WGCNA) was then employed to pinpoint genes linked to sepsis clinical modules significantly associated with the phenotype. An intersection analysis with pyroptosis-related genes was conducted, resulting in the identification of 60 common genes. Then, two core genes (BCL6 and JAK2) were jointly identified using three types of machine learning: random forest, SVM, and Lasso regression. Expression analysis showed that both were significantly highly expressed in the sepsis group, and the subject work characteristic curve (ROC) analysis demonstrated that their diagnostic efficacies were high in both of them in the multiple datasets (AUC value > 0.88), and meta-analysis revealed their correlation with the prognostic status of sepsis patients, and GSEA analysis showed that BCL6 was mainly enriched in metabolism-related pathways, while JAK2 was significantly involved in inflammatory signaling pathways. In addition, immune infiltration analysis showed that BCL6 and JAK2 were closely associated with the infiltration of a variety of immune cells, suggesting their potential functions in regulating the immune microenvironment. Finally, single-cell sequencing localization showed that BCL6 and JAK2 were mainly distributed in macrophages and B cells. Mendelian Randomization Analysis Suggests BCL6, JAK2 Expression Levels May Influence the Risk of Sepsis. The experimental results verified the expression status of key genes. Clinical trial number for this study: ChiCTR1900021261 Registration date: February 4, 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.